The in vitro anti-tumor efficacy and the pharmacokinetics of N 3-O-toluyl-fluorouracil loaded nanosuspension (TFu-LNS)

Journal of Biomedical Nanotechnology

Volumn 9, Issue 5, 2013, Pages 801-810

  Li, Min ^a   Zhang, Juan ^a   Feng, Lixia ^a   Zhang, Li ^a   Zhang, Na ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

5 Fuorouracil (5 Fu); Apoptosis; Cell Cycle; Cytotoxicity; N3 o Toluyl Fluorouracil (TFu); Nanosuspension; Pharmacokinetics

Indexed keywords

5-FUOROURACIL (5-FU); ADENOCARCINOMA CELLS; ANTI-PROLIFERATIVE ACTIVITIES; ANTI-TUMOR EFFICACY; CELL CYCLE; GASTRIC CARCINOMA; HIGH PRESSURE HOMOGENIZATION; NANO-SUSPENSIONS;

CELL CULTURE; CELL DEATH; CYTOTOXICITY; ENZYME INHIBITION; HOMOGENIZATION METHOD; PHARMACOKINETICS;

NUMBER THEORY;

ANTINEOPLASTIC AGENT; FLUOROURACIL; FLUOROURACIL DERIVATIVE; N3 O TOLUYLFLUOROURACIL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL CULTURE; CELL PROLIFERATION; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG STRUCTURE; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; NANOMEDICINE; NONHUMAN; RAT; STOMACH CARCINOMA; SUSPENSION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; FLUOROURACIL; HUMANS; MALE; MATERIALS TESTING; MICE; MICROSOMES, LIVER; NANOSTRUCTURES; PRODRUGS; RATS; RATS, WISTAR; SOLUBILITY; SUSPENSIONS; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84877729855     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2013.1586     Document Type: Article

References (24)

1. T. Shirasaka, Development history and concept of an oral anticancer agent S-1 (TS-1®): Its clinical usefulness and future vistas. Jpn. J. Clin. Oncol. 39, 2 (2009).
2. U. Scherf, D. T. Ross, M. Waltham, L. H. Smith, J. K. Lee, L. Tanabe, K. W. Kohn, W. C. Reinhold, T. G. Myers, and D. T. Andrews, A gene expression database for the molecular pharmacology of cancer. Nat. Genet. 24, 236 (2000).
3. F. Yuan, X. Qin, D. Zhou, Q. Y. Xiang, M. T. Wang, Z. R. Zhang, and Y. Huang, In vitro cytotoxicity, in vivo biodistribution and antitumor activity of HPMA copolymer-5-fluorouracil conjugates. Eur. J. Pharm. Biopharm. 70, 770 (2008).
4. B. T. Yu, X. Sun, and Z. R. Zhang, Enhanced liver targeting by synthesis of N1-stearyl-5-Fu and incorporation into solid lipid nanoparticles. Arch. Pharm. Res. 26, 1096 (2003).
5. J. Liu, X. Li, Y. Cheng, S. Cui, M. Chen, W. Xu, Z. Tian, M. Makuuchi, W. Tang, and X. Qu, Inhibition of human gastric carcinoma cell growth by treatment of N3-o-toluyl-fluorouracil as a precursor of 5-fluorouracil. Eur. J. Pharmacol. 574, 1 (2007).
6. W. Sun, N. Zhang, A. Li, W. Zou, and W. Xu, Preparation and evaluation of N3-O-toluyl-fluorouracil-loaded liposomes. Int. J. Pharm. 353, 243 (2008).
7. W. Zou, W. Sun, N. Zhang, and W. Xu, Enhanced oral bioavailability and absorption mechanism study of N3-O-toluyl-fluorouracil-loaded liposomes. J. Biomed. Nanotechnol. 4, 90 (2008).
8. W. Sun, W. Zou, G. Huang, A. Li, and N. Zhang, Pharmacokinetics and targeting property of TFu-loaded liposomes with different sizes after intravenous and oral administration. J. Drug Target 16, 357 (2008).
9. X. Zhang, J. L. Zhong, W. Liu, Z. Gao, X. Xue, P. Yue, L. Wang, C. Zhao, W. Xu, and X. Qu, N3-o-toluyl-fluorouracil inhibits human hepatocellular carcinoma cell growth via sustained release of 5-FU. Cancer Chemoth. Pharm. 66, 11 (2010).
10. V. Patravale, A. A. Date, and R. Kulkarni, Nanosuspensions: A promising drug delivery strategy. J. Pharm. Pharmacol. 56, 827 (2004).
11. S. Nayak, D. Panda, and J. Sahoo, Nanosuspension: A novel drug delivery system. Journal of Pharmacy Research 3, 241 (2010).
12. H. S. M. Ali, P. York, and N. Blagden, Preparation of hydrocortisone nanosuspension through a bottom-up nanoprecipitation technique using microfluidic reactors. Int. J. Pharm. 375, 107 (2009).
13. D. Zheng, Y. Wang, D. Zhang, Z. Liu, C. Duan, L. Jia, F. Wang, Y. Liu, G. Liu, and L. Hao, In vitro antitumor activity of silybin nanosuspension in PC-3 cells. Cancer Lett. 307, 158 (2011).
14. Y. Liu, D. Zhang, C. Duan, L. Jia, P. Xie, D. Zheng, F. Wang, G. Liu, L. Hao, and X. Zhang, Studies on pharmacokinetics and tissue distribution of bifendate nanosuspensions for intravenous delivery. J. Microencapsul. 29, 194 (2012).
15. H. Lou, X. Zhang, L. Gao, F. Feng, J. Wang, X. Wei, Z. Yu, D. Zhang, and Q. Zhang, In vitro and in vivo antitumor activity of oridonin nanosuspension. Int. J. Pharm. 379, 181 (2009).
16. L. Wang, Z. Liu, D. Liu, C. Liu, Z. Juan, and N. Zhang, Docetaxelloaded- lipid-based-nanosuspensions (DTX-LNS): Preparation, pharmacokinetics, tissue distribution and antitumor activity. Int. J. Pharm. 413, 194 (2011).
17. J. Liu, W. Xu, Y. Zhou, Y. Yuan, and X. Qu, Effect of growth inhibition on tumour cells induced by N3-O-Toluyl-flulorouracil. Chinese Joumal of Pharmaceutical 37, 252 (2006).
18. W. Liu, S. Xie, W Xu, and X. Qu, N3-O-toluyl-flulorouracil inhibit human hepatocellular carcinoma cell growth and analysis of biotransformation. Chinese Journal of Pharmaceutical Analysis 28, 1815 (2008).
19. J. Zhang, Studies on TFu-Loaded Nanosuspensions, Shandong University (2012).
20. L. Tang, J. Zhou, C. Yang, B. Xia, M. Hu, and Z. Liu, Systematic studies of sulfation and glucuronidation of 12 flavonoids in the mouse liver S9 fraction reveals both unique and shared positional preferences. J. Agr. Food Chem. 60, 3223 (2012).
21. J. Zhang, M. Li, Z. Liu, L. Wang, and Y. Liu, Preclinical Studies Of N3-O-toluyl-fluorouracil-loaded-lipid-based-Nanosuspensions (TFu- LNS) In H22 Bearing Mice. Pharmaceutical Research. Revised for publication.
22. W. Sun, Studies on the TFu-loaded liposomes, School of Pharmaceutical Science, Shandong University (2007).
23. G. Sandri, M. C. Bonferoni, S. Rossi, F. Ferrari, S. Gibin, Y. Zambito, G. Di Colo, and C. Caramella, Nanoparticles based on N-trimethylchitosan: Evaluation of absorption properties using in vitro (Caco-2 cells) and ex vivo (excised rat jejunum) models. Eur. J. Pharm. Biopharm. 65, 68 (2007).
24. N. Arunkumar, M. Deecaraman, and C. Rani, Nanosuspension technology and its applications in drug delivery. Asian Journal of Pharmaceutics 3, 168 (2009).